Leojaponin is a prolyl oligopeptidase (POP) inhibitor. Leojaponin exhibits significant cytoprotective activities against glutamate-induced toxicity at concentrations ranging from 0.1 microm to 10 microm.
Apoptin-derived peptide, an antitumor polypeptide, exhibits cytotoxic effects by promoting apoptosis and necrosis in gastric cancer (GC) cells through the modulation of the PI3K AKT ARNT signaling pathway. It also impedes both the invasion and migration of cancer cells by inhibiting the expression and phosphorylation of the p85 subunit of PI3K, subsequently suppressing the PI3K AKT pathway critical to gastric cancer development [1].